Recursion Pharmaceuticals, Inc. (RXRX)

Recursion Pharmaceuticals Revenue

Recursion Pharmaceuticals had revenue of $7.67M in the quarter ending June 30, 2026, a decrease of -60.10%. This brings the company's total for the last twelve months to $54.86M, down -15.08% year-over-year. In the year 2025, Recursion Pharmaceuticals had annual revenue of $74.68M with 26.92% growth. That makes Recursion Pharmaceuticals the 27,284th largest company in the world by revenue and 3,715th in the United States.

• Revenue (ttm): $54.86M
• Revenue Growth: -15.08%
• P/S Ratio: 41.41
• Revenue / Employee: $91,427
• Employees: 600
• Market Cap: 2.27B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Research and Development Agreements 74.26M 99.4%
• Grant 425.00K 0.6%

By Geography

Chart

• United States 39.34M 52.7%
• United Kingdom 35.34M 47.3%

Fiscal year ended Dec 31, 2025 See the full Recursion Pharmaceuticals breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	74.68M	15.84M	26.92%
Dec 31, 2024	58.84M	14.26M	32.00%
Dec 31, 2023	44.58M	4.73M	11.88%
Dec 31, 2022	39.84M	29.67M	291.46%
Dec 31, 2021	10.18M	6.22M	156.89%
Dec 31, 2020	3.96M	1.64M	70.85%
Dec 31, 2019	2.32M	-	-

Data Source: Fiscal.ai Last updated: Aug 5, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 25, 2026

Data Sources Report a data error